|
- Novartis Pharmathen decision confirmed on appeal - BarentsKrans
By judgment of 26 March 2024 in PI proceedings brought by Novartis AG, the Court of Appeal of Amsterdam confirmed that Pharmathen must pay € 7 500 000 in penalties forfeited for breach of an injunction imposed for patent infringement
- Patent case: Pharmathen Global B. V. vs. Novartis AG . . .
After Novartis had obtained a preliminary injunction against Pharmathen, it observed that there were still infringing acts being performed In the first instance, the provisions judge sided with Novartis and ordered that Pharmathen had to pay EUR 7,500,000 as a penalty
- NL - Pharmathen Global v. Novartis Supreme Court - EPLAW
The preliminary relief judge has imposed an injunction on Pharmathen Global to act unlawfully, an (in)direct infringement ban in the Netherlands and the other countries in which EP 519 is in force and ordered it to instruct third parties, including its subsidiary Pharmathen Greece, to cease and desist from patent infringement
- Dutch court halts sale of Pharmathen cancer drug Okrodin in . . .
The District Court of The Hague has issued a cross-border preliminary injunction, in a dispute over a cancer drug between Novartis and pharmaceutical company Pharmathen The ruling prevents the company from selling the drug to distributors anywhere in Europe where the patent is in force 23 August 2022 by Joshua Silverwood
- Novartis Pharmathen decision confirmed on appeal - Lexology
On 19 July 2022, the District Court of The Hague had ruled that there is the threat that Pharmathen would induce its Greek subsidiary Pharmathen SA to infringe EP 519 and, by doing this,
- Novartis vs. Pharmathen: Octreotide – Ipessentia
Supreme Court upheld previous decisions, barring Pharmathen Global BV from commercializing generic octreotide across Europe Pharmathen must pay €7 5 million penalty to Novartis for non-compliance with the 2022 injunction
- Hoge Raad verwerpt cassatieberoep Pharmathen Global tegen . . .
In een recente uitspraak heeft de Hoge Raad het cassatieberoep van Pharmathen Global B V tegen Novartis A G verworpen Deze zaak draaide om octrooi-inbreuk en de vraag of feitelijk leidinggeven aan inbreukmakende handelingen als een voorbehouden handeling geldt
|
|
|